Compare WILC & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WILC | TECX |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.5M | 359.0M |
| IPO Year | 1997 | 2018 |
| Metric | WILC | TECX |
|---|---|---|
| Price | $29.02 | $20.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $81.20 |
| AVG Volume (30 Days) | 12.8K | ★ 319.1K |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 64.86 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $180,746,882.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.02 | ★ N/A |
| Revenue Growth | ★ 4.22 | N/A |
| 52 Week Low | $12.54 | $13.70 |
| 52 Week High | $30.89 | $61.07 |
| Indicator | WILC | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 70.17 | 54.18 |
| Support Level | $28.61 | $20.54 |
| Resistance Level | $30.89 | $22.00 |
| Average True Range (ATR) | 0.75 | 1.07 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 54.62 | 68.41 |
G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.